Chapman Corporation v. Teddy Kemp ( 2023 )


Menu:
  •                                                                                   FILED
    April 5, 2023
    EDYTHE NASH GAISER, CLERK
    SUPREME COURT OF APPEALS
    OF WEST VIRGINIA
    STATE OF WEST VIRGINIA
    SUPREME COURT OF APPEALS
    CHAPMAN CORPORATION,
    Employer Below, Petitioner
    vs.)   No. 21-0501 (BOR Appeal No. 2056170)
    (Claim No. 2019017083)
    TEDDY KEMP,
    Claimant Below, Respondent
    MEMORANDUM DECISION
    Petitioner Chapman Corporation, by counsel Lisa Warner Hunter, appeals the decision of
    the West Virginia Workers’ Compensation Board of Review (“Board of Review”). Teddy Kemp,
    by counsel R. Dean Hartley, filed a timely response.
    The issue on appeal is compensability. The claims administrator rejected the claim on May
    31, 2019. The Workers’ Compensation Office of Judges (“Office of Judges”) reversed the decision
    in its December 9, 2020, Order and held the claim compensable for chronic lymphocytic leukemia
    (“CLL”). The Order was affirmed by the Board of Review on May 20, 2021.
    The Court has carefully reviewed the records, written arguments, and appendices contained
    in the briefs, and the case is mature for consideration. The facts and legal arguments are adequately
    presented, and the decisional process would not be significantly aided by oral argument. Upon
    consideration of the standard of review, the briefs, and the record presented, the Court finds no
    substantial question of law and no prejudicial error. For these reasons, a memorandum decision is
    appropriate under Rule 21 of the Rules of Appellate Procedure.
    The standard of review applicable to this Court’s consideration of workers’ compensation
    appeals has been set out under 
    W. Va. Code § 23-5-15
    , in relevant part, as follows:
    (c) In reviewing a decision of the Board of Review, the Supreme Court of
    Appeals shall consider the record provided by the board and give deference to the
    board’s findings, reasoning, and conclusions . . . .
    (e) If the decision of the board effectively represents a reversal of a prior
    ruling of either the commission or the Office of Judges that was entered on the same
    1
    issue in the same claim, the decision of the board may be reversed or modified by
    the Supreme Court of Appeals only if the decision is in clear violation of
    constitutional or statutory provisions, is clearly the result of erroneous conclusions
    of law, or is so clearly wrong based upon the evidentiary record that even when all
    inferences are resolved in favor of the board’s findings, reasoning, and conclusions,
    there is insufficient support to sustain the decision. The court may not conduct a de
    novo reweighing of the evidentiary record . . . .
    See Hammons v. W. Va. Off. of Ins. Comm’r, 
    235 W. Va. 577
    , 582-83, 
    775 S.E.2d 458
    , 463-64
    (2015). As we previously recognized in Justice v. West Virginia Office Insurance Commission,
    
    230 W. Va. 80
    , 83, 
    736 S.E.2d 80
    , 83 (2012), we apply a de novo standard of review to questions
    of law arising in the context of decisions issued by the Board. See also Davies v. W. Va. Off. of
    Ins. Comm’r, 
    227 W. Va. 330
    , 334, 
    708 S.E.2d 524
    , 528 (2011).
    Mr. Kemp, an electrician, alleges that he developed CLL as a result of occupational
    benzene exposure while working at Chapman Corporation and filed an Employees’ and
    Physicians’ Report of Occupational Injury or Disease. In his application, Mr. Kemp stated that
    over his thirty-nine year career, he was exposed to numerous chemicals, including but not limited
    to benzene and/or benzene-containing chemicals or products, which have been shown to cause
    cancer. Mr. Kemp reported that he was first diagnosed with CLL through a bone marrow exam on
    February 17, 2016.
    The physician’s section of the claim application was completed by Amit Mehta, M.D., who
    indicated that Mr. Kemp had developed CLL as a result of his occupational exposure. In Dr.
    Mehta’s medical report dated November 1, 2018, Mr. Kemp’s CLL was characterized as
    “moderate” in severity and “daily” in frequency. It was noted that Mr. Kemp is a retired electrical
    contractor at two facilities, PPG Industries, Inc. (“PPG”) and the Mobay/Bayer New Martinsville
    plant (“Mobay/Bayer”), where he was exposed to chemicals, including benzene, over a period of
    nearly forty years. He reported that he had to breathe fumes daily and did not recall wearing masks,
    gloves, or other safety equipment on a regular basis. There were occasional episodes of direct
    chemical contact with his skin. Dr. Mehta noted that multiple studies exist supporting the link “of
    longer exposure and degree of exposure and CLL link.” These included a “systematic meta-
    analysis published in the journal of Environmental Health in 2010 by Khalade A. et. al., which
    found an odds ratio of 1.31 (31% increased risk) for the development of CLL from exposure.” The
    study found that those with a higher exposure had a statistically significant trend towards a higher
    risk of developing CLL. Considering Mr. Kemp’s daily exposure to benzene for nearly forty years,
    and the absence of any other risk factors, including no family history of leukemia or lymphoma,
    Dr. Mehta opined that it was more likely than not that benzene exposure led to Mr. Kemp’s
    development of CLL.
    The claims administrator rejected the claim on May 31, 2019. The Order stated, “[t]here
    isn’t any evidence which causally relates your diagnosis of Chronic Lymphocytic Leukemia to
    your employment with Chapman Corporation.” Mr. Kemp protested the claims administrator’s
    decision.
    2
    Mr. Kemp’s deposition was taken on November 4, 2019, regarding his alleged benzene
    exposure and diagnosis of CLL. When asked when his symptoms started, Mr. Kemp indicated that
    in 2011 his blood tests began showing high white blood cell counts. Although he is not receiving
    any treatment for his diagnosis of CLL, his condition is being monitored every six months to
    measure his white blood count. Mr. Kemp’s mother and brother died of lung cancer. Both were
    heavy smokers. Although he is not a cigarette smoker, Mr. Kemp’s parents smoked in the house
    until his father quit when he was around eighth grade. Mr. Kemp testified that his alleged exposure
    to benzene started in August 1975 while working at PPG doing electrical work in all departments
    all over the plant. Mr. Kemp worked in those areas of the Mobay/Bayer plant where benzene was
    stored and processed, including the tank farm, mononitrobenzene (“MNB”) area, and above the
    waste-water trench. His work as an electrician in the MNB area required him to stand over the
    vessels as he was working on the instruments in the tank. Mr. Kemp testified that he was exposed
    to benzene and materials containing benzene in the vessels. Most of his career, he alleged that he
    could smell a sweet odor on a regular basis while in areas of the Mobay/Bayer plant. He denied
    any training or use of any type of facemask or respirator during all of his employment. Mr. Kemp
    last worked for the employer in February 2009. He then worked at the Mitchell powerhouse, where
    he was not exposed, to his knowledge, to benzene. Mr. Kemp later worked for Longview
    powerhouse doing the same type of work. There is no indication in the record whether Mr. Kemp
    was exposed to benzene while working for Longview.
    Mr. Kemp introduced a letter from Peter Infante Consulting, LLC, on November 20, 2019,
    along with a report of Peter F. Infante, D.D.S., F.A.C.E. The firm is an organization dedicated to
    occupational and environmental health. In the November 20, 2019, report, Dr. Infante, stated that
    he has held multiple positions as professor, director, and consultant for occupational health,
    carcinogen identification, and epidemiology. Dr. Infante worked for the International Agency for
    Research on Cancer (“IARC”) and was invited to meetings held in 2009 and 2017. The purpose of
    the meetings was to evaluate chemical and workplace exposure, including benzene. Dr. Infante
    conducted epidemiological studies of workers exposed to chemicals, including benzene. Dr.
    Infante stated that he has conducted major research on benzene toxicity to humans and received a
    Special Commendation from the United States Public Health Services, Centers for Disease
    Control, and NIOSH. Dr. Infante opined that occupational exposure to benzene can cause CLL. In
    support of his conclusion, he cited thirty-five pages of case reports, epidemiological studies, meta-
    analyses, mortality studies, governmental agency reports, industry studies, and a biological
    plausibility assessment. Dr. Infante also analyzed the association between benzene exposure and
    the risk of developing CLL using the Bradford-Hill criteria and concluded that all of the
    meaningful viewpoints related to causality are met in relation to benzene exposure and CLL. In
    his opinion, the Bradford-Hill analysis adds support to his conclusion that there is a causal
    association between exposure to benzene and to benzene-containing solvents and the development
    of CLL.
    Dr. Mehta testified in a deposition on December 4, 2019, that he is a hematologist and
    oncologist and is board certified in both specialties. Dr. Mehta stated that he examined Mr. Kemp
    and reviewed his records. He concluded that Mr. Kemp’s significant history of occupational
    exposure to benzene and benzene-containing products resulted in his CLL. Dr. Mehta considered
    Mr. Kemp’s exposure to be clinically significant due to the direct nature of the contact, the
    3
    frequency of the contact, and the intensity of the exposure. Dr. Mehta noted that Mr. Kemp’s
    exposure would put him at risk based upon known literature regarding the potential causation
    between benzene exposure and CLL. Dr. Mehta asserted that there is a large amount of medical
    literature establishing a link between benzene exposure and CLL. He further asserted that it is the
    conclusion of most hematologists that benzene causes CLL. Dr. Mehta opined that Mr. Kemp’s
    significant benzene exposure was sufficient to cause CLL. He testified that Mr. Kemp had no other
    risk factors for the disease, including a family history of leukemia. Further, Mr. Kemp had a deleted
    13q chromosome, which is consistent with benzene-induced leukemia. Dr. Mehta testified that
    based upon Mr. Kemp’s medical presentation, his reported occupational exposure history, and the
    absence of any other known risk factors for the development of CLL, he believes that Mr. Kemp’s
    occupational exposure to benzene was the “proximate cause of his developing chronic leukemia.”
    Christopher Martin, M.D., performed a Record Review on March 3, 2020, in which he
    noted that Mr. Kemp was seventy years old at the time of the review and had been diagnosed with
    CLL by Catherine Swift, M.D., on February 17, 2016. Based upon his review of the records, Dr.
    Martin concluded that Mr. Kemp had a diagnosis of CLL. Although he stated that it is possible,
    but not established, that Mr. Kemp was exposed to excessive levels of benzene through his work,
    Dr. Martin opined to a reasonable degree of medical certainty that the evidence did not support a
    finding that Mr. Kemp’s CLL was the result of his occupational exposure to benzene. Dr. Martin
    stated that the National Cancer Institute and American Cancer Society (“ACS”) provides that the
    median age for a diagnosis of CLL is sixty-eight years, and it is most common among males of
    Caucasian ethnicity. Dr. Martin opined that Mr. Wells fits the typical profile for a diagnosis of
    CLL among the general population. He further opined that benzene cannot be regarded as an
    accepted risk factor for CLL, because the ACS does not list benzene as a risk factor for developing
    CLL. Dr. Martin acknowledged that the IARC classified benzene as a Group 1 carcinogen;
    however, the classification is based on leukemia/acute non-lymphocytic leukemia. While Dr.
    Martin noted that the IARC believed there was a positive association between benzene exposure
    and CLL, the IARC did not believe the association rose to the level of supporting a conclusion that
    it was medically reasonable to infer a causal relationship.
    Dr. Martin disagreed with Dr. Mehta’s findings that Mr. Kemp’s CLL was symptomatic in
    the form of recurrent infections and fatigue resulting in the need for immunoglobulin infusions.
    Dr. Martin did not believe that such an opinion is supported by the records of the treating
    oncologist and his primary care physician. Dr. Martin also took issue with the Khalade et. al. study
    cited by Dr. Mehta. He explained that the most methodologically sound study on benzene and CLL
    was published in 2017 by Talibov et. al., and included 20,615 cases of CLL diagnosed in 1961-
    2005. Dr. Martin summarized that this study did not demonstrate the association between solvent
    exposure and adult CLL.
    The Office of Judges reversed the claims administrator’s rejection of the claim and held
    the claim compensable for CLL in its December 9, 2020, Order. First, the Office of Judges found
    that the weight of the medical record clearly establishes that Mr. Kemp has a diagnosis of CLL.
    Second, the Office of Judges concluded that Mr. Kemp had significant occupational exposure to
    benzene, and he testified that he was exposed to benzene and benzene containing products for his
    thirty-nine years of employment working as an electrician at the Mobay/Bayer chemical plant.
    4
    According to Mr. Kemp’s affidavit, benzene-containing products were produced at PPG and
    Mobay/Bayer plants. The PPG plant produced MCB, orthodichlorobenzene, and
    paradichlorobenzene, while the Mobay/Bayer plant produced mononitrated benzene. While
    working in the PPG plant for two years, Mr. Kemp stated that the chemical tank pumps leaked and
    were sometimes overfilled. He also could smell the sweet odor of benzene while working in the
    MCB department. Mr. Kemp worked in the MNB department at the Mobay/Bayer plant, and he
    was exposed to benzene and material containing benzene while performing electrical work on the
    instruments in the MNB department, where chemical upsets, overfills of the tanks, and leaking
    tank pumps were a regular occurrence. Mr. Kemp also worked around a waste-water trench which
    was comprised of chemical upsets in the MNB process. The Office of Judges found that Mr. Kemp
    testified that he was exposed to the sweet odor of benzene from the trench on a daily basis. He
    worked at the Mobay/Bayer plant for approximately twenty years. While working for the Chapman
    Corporation at the Mobay/Bayer plant, Mr. Kemp was tasked with replacing and rewiring large
    electric motors that exposed him to various chemicals. He also worked around trenches that
    contained chemical waste and over top of the trenches on man-lifts and walking cables. The sweet
    smell of benzene was also observed while working near the trenches. The Office of Judges
    determined that Mr. Kemp submitted sufficient evidence to show, that more likely than not, he
    was regularly exposed to significant amounts of benzene during the course of and as a result of his
    employment as an electrician. It was also found that Mr. Kemp’s testimony and Dr. Mehta’s
    medical report support such a finding.
    Third, the Office of Judges determined that the weight of the medical evidence establishes
    that benzene exposure can cause CLL. It found that Drs. Mehta and Infante both opined that
    numerous studies have shown a causal connection between benzene exposure and CLL. Dr. Infante
    is a professional epidemiologist with an extensive resume. In support of his position, Dr. Infante
    submitted over thirty pages of case reports, epidemiological studies, meta-analyses, mortality
    studies, governmental agency reports, industry studies, and a biological plausibility assessment.
    The Office of Judges noted that Dr. Mehta is a hematologist and oncologist who primarily works
    with hematologic malignancies, such as leukemia and lymphoma. Dr. Mehta opined that Mr.
    Kemp’s benzene exposure more likely than not caused his CLL. Chapman Corporation argued that
    benzene does not cause CLL and relied on the report of Dr. Martin. The Office of Judges noted
    that Dr. Martin is an occupational medicine physician who opined that the medical evidence did
    not support a finding that Mr. Kemp’s CLL was causally related to his occupational exposure to
    benzine. In support of his position, Dr. Martin cited articles from the National Cancer Institute
    and the American Cancer Society and stated that Mr. Kemp fits the typical age, gender, and
    ethnicity of someone diagnosed with CLL in the general population. Dr. Martin also noted that the
    American Cancer Society did not specifically list benzene as a risk factor for CLL.
    After reading the literature and reports of the experts, the Office of Judges determined that
    there is no consensus in the medical community regarding a causal link between benzene exposure
    and CLL. On one side, Drs. Infante and Mehta assert that benzene exposure causes CLL, and on
    the other, Dr. Martin argues the opposite. Both sides cited numerous medical reports, studies, and
    literature in support of their positions. The Office of Judges noted that both Drs. Martin and Infante
    stated that opinions on causality in this context are professional judgment calls. The Office of
    Judges agreed. It found that Dr. Infante is an award winning professional epidemiologist with a
    5
    focus on occupational environmental epidemiology. He has written numerous articles on benzene
    exposure and its risks and has served as an expert witness in hundreds of cases. Dr. Mehta is a
    hematology and oncology physician who specializes in hematologic malignancies, such as
    leukemia and lymphoma. On the other side, Dr. Martin is an occupational medicine physician. The
    Office of Judges concluded that Drs. Infante and Mehta were more qualified in the area of benzene
    exposure and CLL causality than Dr. Martin. Further, the Office of Judges found that the opinions
    of Drs. Infante and Mehta support each other, whereas there is no medical opinion of record in
    support of Dr. Martin’s findings. The Office of Judges therefore determined that the opinions of
    Drs. Infante and Mehta were the most persuasive medical opinions of record.
    The Office of Judges noted that West Virginia Code § 23-4-1 provides the standard for
    compensability of occupational diseases. It requires
    “(1) that there is a direct causal connection between the conditions under which
    work is performed and the occupational disease; (2) that it can be seen to have
    followed as a natural incident of the work as a result of the exposure occasioned
    by the nature of the employment; (3) that it can be fairly traced to the
    employment as the proximate cause; (4) that it does not come from a hazard to
    which workmen would have been equally exposed outside of the employment;
    (5) that it is incidental to the character of the business and not independent of the
    relation of an employer and employee; and (6) that it appears to have had its
    origin in the risk connected with the employment and to have flowed from that
    source as a natural consequence, though it need not have been foreseen or
    expected before its contraction.”
    The Office of Judges found that the weight of the medical evidence supports a finding that
    Mr. Kemp’s CLL was caused by his occupational exposure to benzene. The record establishes that
    he was exposed to significant amounts of benzene and benzene-containing products during his
    over thirty-nine years of employment, that he has a diagnosis of CLL, and that benzene exposure
    can cause CLL. The Office of Judges found that Dr. Mehta specifically opined that it was
    reasonably probable to conclude that Mr. Kemp developed CLL as a result of his exposure to
    benzene at work. The only medical evidence submitted by the employer to refute Dr. Mehta’s
    opinion is the record review by Dr. Martin, which was not found to be as reliable.
    The Office of Judges concluded that Mr. Kemp established a prima facia case for CLL due
    to occupational benzene exposure by showing that (1) a causal connection exists between the
    conditions under which his work was performed and his diagnosis of CLL, (2) that his CLL was a
    natural incident of his work as a result of exposure to benzene, (3) that the proximate cause of his
    CLL can be traced to his employment, (4) that his CLL did not develop as the result of a non-
    occupational hazard, (5) that the exposure which resulted in CLL was incidental to the character
    of the employer’s business, and (6) that his development of CLL originated in a risk connected to
    his employment and flowed as a result of that employment. The Office of Judges held the claim
    compensable for CLL. The Board of Review adopted the findings of fact and conclusions of law
    of the Office of Judges and affirmed its Order on May 20, 2021.
    6
    After review, we agree with the reasoning and conclusions of the Office of Judges as
    affirmed by the Board of Review. Mr. Kemp presented sufficient evidence that he had significant
    exposure to benzene throughout his thirty-nine years of employment and that such exposure
    resulted in the development of CLL. The Office of Judges and Board of Review did not err in
    finding that Mr. Kemp submitted sufficient evidence to find his claim compensable under West
    Virginia Code § 23-4-1.
    Affirmed.
    ISSUED: April 5, 2023
    CONCURRED IN BY:
    Chief Justice Elizabeth D. Walker
    Justice Tim Armstead
    Justice John A. Hutchison
    Justice William R. Wooton
    Justice C. Haley Bunn
    7